2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1633

Ulodesine (BCX4208) Add-On Therapy to Allopurinol 300mg Lowers Hypoxanthine and Xanthine Plasma Levels in a Dose-Dependent Fashion: Results From a 12-Week Randomized Controlled Trial in Patients with Gout
Abstract Number: 150

Ulodesine (BCX4208) Long-Term Safety When Added to Allopurinol in the Chronic Management of Gout: A Phase 2 24-Week Blinded Safety Extension and Vaccine Challenge Study
Abstract Number: 1351

Ultrasonographic Entheseal Abnormalities Among Patients with Psoriatic Arthritis, Psoriasis Alone and Healthy Individuals and Their Correlation with Disease-Related Variables
Abstract Number: 127

Ultrasonographic Evaluation of the Hands of Patients with Primary and Secondary Sjögren´s Syndrome
Abstract Number: 1379

Ultrasonographic Is More Sensitive Than Traditional Clinical Evaluation in the Detection of Hands and Wrists Synovitis and Digital Soft Tissue Involvement in Early Psoriatic Arthritis
Abstract Number: 2186

Ultrasonography of Major Salivary Glands in Primary Sjögren’s syndrome
Abstract Number: 126

Ultrasonography of Salivary Glands: Diagnostic and Prognostic Value in Primary Sjögren’s Syndrome
Abstract Number: 809

Ultrasonography Predicts Achievement of Deeper Remission After DAS28-Based Clinical Remission of Rheumatoid Arthritis
Abstract Number: 119

Ultrasound (US) Findings in Patients with Knee Pain: Sensitivity and Specificity for the Diagnosis of Knee Osteoarthritis and Development of an US Prediction Score
Abstract Number: 117

Ultrasound for Diagnosis of Carpal Tunnel Syndrome – Comparison of Different Methods to Determine Median Nerve Volume and Value of Power Doppler Sonography
Abstract Number: 111

Ultrasound Measurement of Metacarpal Cartilage Thickness Correlates with Joint Space Narrowing in the Metacarphalangeal Joints of Patients with Rheumatoid Arthritis
Abstract Number: 1044

Ultrasound Scores of Enthesitis and Dactylitis Do Not Correlate with Corresponding Clinical Findings in Psoriasis Arthritis
Abstract Number: 2636

Understanding Why Treat-to-Target Strategies Are Difficult to Follow
Abstract Number: 1460

Unmasking Latent Pulmonary Arterial Hypertension by Fluid Challenge in Patients with Systemic Sclerosis
Abstract Number: 658

Up-Regulation of A Disintegrin and Metalloprotease with Thrombospondin Type I Repeats-13 Correlates with Ischemic Cerebrovascular Disease in Systemic Lupus Erythematosus Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].